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TWO {Met(0)6}deacetyl-thymosin  b 4 analogs  contain-
ing Phe(4F)  or  Tyr(Me)  at  position 12 were synthe-
sized  by  the manual  solid-phase  method,  and  their
anti-inflammatory  effect  on  carrageenin-induced
edema in the mouse paw was studied. Fluorination of
the para-position of Phe12 resulted in a marked anti-
inflammatory  effect  on  carrageenin-induced  edema
in  the  mouse  paw  compared  with  that  of  our  syn-
thetic  {Met(0)6}deacetyl-thymosin  b 4,  but  the  other
analog,  {Met(0)6,  Tyr(Me)12}deacetyl-thymosin  b 4,
showed a marked reduction of the anti-inflammatory
effect.
Key  words: Anti-inflammatory  effect,  [Met(0)6]deacetyl-
thymosin  b 4 analogue  synthesis,  Carrageenin-induced
edema, Mouse paw
Introduction
Thymosin b 4 consists of 43 amino acid residues (Fig.
1) with a molecular weight of 4963 and an isoelectric
point  of  5.1.1 The  N-terminus  of  the  peptide  is
blocked  by  an  acetyl  group. This  peptide  exhibits
important  activities  in  the  regulation  and  differ-
entiation of thymus-dependent lymphocytes.
Recently, Young et al.2 reported that [Met(0)6]thy-
mosin b 4 (Met(0), methionine sulfoxide) is generated
by monocytes in the presence of glucocorticoids and
acts as a signal to inhibit an inflammatory response,
and [Met(0)6]thymosin b 4 was a potent inhibitor of
carrageenin-induced edema in the mouse paw. [Met-
(0)6]thymosin b 4 may have value in anti-inflammatory
drug  therapy,  with  great  potent  advantages  over
existing nonsteroidal drugs that alleviate the distress-
ing  symptoms  of  inflammation  without  preventing
the tissue damage. Therefore, [Met(0)6]thymosin  b 4
might be able to reproduce the considerable benefits
of  glucocorticoids  originally  seen  in  rheumatoid
arthritis, but without the subsequent disabling steroid
toxicity.
In our  preceding paper,3 we concluded that the
acetyl group at the N-terminal Ser residue of thymo-
sin b 4 is not required for immunological activity. We
have  also  reported4 that  our  synthetic  [Phe(4F)12]
deacetyl-thymosin b 4 (Phe(4F), para-fluorophenylala-
nine)  which  has  the  strong  electron-withdrawing
fluoride atom on the para position of the aromatic
ring  of  deacetyl-thymosin  b 4,  showed  stronger
immunological  activity  than  that  of  our  synthetic
deacetyl-thymosin  b 4. These results prompted us to
synthesize  two  deacetyl-thymosin  b 4 analogs:
[Met(0)6, Phe(4F)12]deacetyl-thymosin b 4, which has
an electron-withdrawing atom (F) at the 12 position
of [Met(0)6]deacetyl-thymosin  b 4; and [Met(0)6, Tyr-
(Me)12]deacetyl-thymosin  b 4, which has an electron-
donating group (-OCH3) at the 12 position of [Met-
(0)6]deacetyl-thymosin  b 4.
This  paper  presents  the  syntheses  of  [Met(0)6,
Phe(4F)12]deacetyl-thymosin  b 4 and  [Met(0)6,  Tyr-
(Me)12]deacetyl-thymosin  b 4, and an examination of
the  comparative  anti-inflammatory  effect  of  these
analogs on carrageenin-induced edema in the mouse
paw.
Materials and methods
9-Fluorenylmethoxycarbonyl (Fmoc) amino acid der-
ivatives  and  Fmoc-Ser(tert-butyl)-phenylacetoamido-
methyl  (Pam)  resin  (0.64mmol/g,  100–200mesh)
were purchased from Kokusan Chemical Works Ltd.
(Japan), Watanabe Chemical Industries Ltd. (Japan),
Peptide Institute Inc. (Japan) and Sigma Chemical Co.
(USA). Thin-layer chromatography (TLC) was effected
with  silica  gel  (Kieselgel  60  F254;  Merck)  on  pre-
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FIG. 1. Amino acid sequence of thymosin b 4.
Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-
Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-
Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-
Gln-Ala-Gly-Glu-Ser-OHcoated  aluminum  sheets  using  n-BuOH-acetic  acid-
pyridine-H2O  as  a  solvent  system.  Analytical  high-
performance  liquid  chromatography  (HPLC)  and
amino acid analysis were conducted with a Shimadzu
LC-6A and a Hitachi 835A, respectively. The fast atom
bombardment mass spectrometry (FAB-MS) spectrum
was obtained on a UG analytical 2-AB-2SEQ spectrom-
eter equipped with the 11–250J data system.
Solid-phase peptide synthesis
Peptide  synthesis  was  performed  manually  by  the
stepwise solid-phase method with a hand-made pep-
tide synthesizer, using the base-labile Fmoc group for
protecting the b -amino groups, and such acid-labile
groups  as  tert-butyl  for  the  hydroxy  and  carboxy
groups, tert-butyloxycarbonyl for the b -amino groups
of Lys, and sulfoxide for Met.
The  peptide  was  assembled  on  Fmoc-Ser(tert-
butyl)-Pam resin. The Fmoc group was removed with
30%  piperidine  in  N,N9 -dimethylformamide  (DMF).
Elongation of the peptide chain was carried out by
the  dicyclohexylcarbodiimide-1-hydroxybenzotria-
zole  (DCC-HOBT)  method  in  CH2Cl2-DMF  (1:1)  or
N-methyl-2-pyrrolidone.  The  coupling  reaction  and
deprotection of the Fmoc group were monitored by
the ninhydrin test. The general  procedure for each
synthetic cycle (starting material, 0.64mmol/g Fmoc-
Ser(tert-butyl)-Pam  resin  (400mg))  was:  (1)  CH2Cl2
wash (twice); (2) DMF wash (twice); (3) deprotect in
DMF-piperidine  (7:3)  for  20min;  (4)  DMF  wash
(twice);  (5)  dioxane-water  (2:1)  wash  (twice);  (6)
DMF  wash  (three  times);  (7)  CH2Cl2 wash  (three
times); (8) addition of 3 equivalents (eq) Fmoc-amino
acid,  HOBT,  and  DCC  in  CH2Cl2-DMF  (1:1)  or
N-methyl-2-pyrrolidone;  (9)  add  l.0ml  diisopropyle-
thylamine in CH2Cl2; (10) reaction for 120min; (11)
recoupling if necessary by repeating steps 7–10; (12)
DMF  wash  (three  times);  (13)  isopropanol  wash
(three  times);  and  (14)  CH2Cl2 wash  (four  times).
Whenever the ninhydrin test was still slightly positive,
even after three couplings, the remaining unreacted
amino  groups  were  acetylated  with  0.4M  acetyl-
imidazole in DMF (1x, 30min), and (step 15) DMF
wash  (twice).  The  protected  resin  thus  obtained
(200mg) was treated with 2M tetrafluoroboric acid–
thioanisole in trifluoroacetic acid (TFA) (7ml) in the
presence  of  m-cresol  (218 m l,  100eq)  and  ethane-
1,2-diol (524m l, 300eq) at 4°C for 90min.
After the deprotection, the resin was removed by
filtration  and  the  filtrate  was  evaporated  under
reduced pressure, and the residue was solidified by
addition of anhydrous ether to give a crude peptide.
The resulting  powder was dissolved in H2O  (6ml).
The  solution  was  treated  with  Amberlite  CG-4B
(acetate  form,  approximately  3g)  for  30min,  and
filtered  by  suction  and  evaporated  in  vacuo. The
residue was dissolved in a small amount of 1% acetic
acid and then applied to a column of Sephadex G-25
(2.3  ´ 96cm),  which  was  eluted  with  the  same
solvent.  Individual  fractions  (5ml  each)  were  col-
lected and absorbancy at 260nm was determined for
each  fraction.  The  fractions  corresponding  to  the
front main peak were combined and the solvent was
removed by lyophilization. The peptide was further
purified  by  semi-preparative  PR-HPLC.  The  semi-
preparative PR-HPLC was performed on a Nucleosil
C18 column (250 ´ 10mm I.D.; 7 m m particle size;
Marcherey Nagel). Solvent A was 0.05% TFA in water
and  solvent  B  was 60%  acetonitrile in  solvent A. A
linear gradient was applied from 10 to 50% B during
50min, at a flow rate of 3.0ml/min. Detection of the
peptide  was  set  at  230nm.  The  major  peak  was
lyophilized to give the purified product. Overall yields
of  the  two  peptides  were  5.9%  ([Met(0)6,  Phe-
(4F)12]deacetyl-thymosin  b 4)  and  6.1%  ([Met(0)6,
Tyr(Me)12]deacetyl-thymosin  b 4), respectively, based
on the C-terminal Ser loaded on the resin. Homoge-
neity of the peptides was checked by TLC, analytical
HPLC, FAB-MS, and amino acid analysis after 6N HCl
hydrolysis, The physicochemical data of the synthetic
analogs are presented in Tables 1 and 2.
Bioassay
Carrageenin-induced  inflammation  was  initiated  in
BALB/C  mice  as  described elsewhere.5 One  of  the
three  analogs,  [Met(0)6]deacetyl-thymosin  b 4
T. Abiko and R. Ogawa
90 Mediators of Inflammation · Vol 10 · 2001
Table 1. Characterization of  synthetic  [Met(0)
6,  Phe(4F)
12]deacetyl-thymosin  b 4 and [Met(0)
6,
Tyr(Me)
12]deacetyl-thymosin b 4
Peptide
[a]
21
D
(c = 0.5,
1% acetic acid)
TLC
a
Rf
HPLC
b FAB-MS
c
(NH
+)
[Met(0)
6, Phe(4F)
12]deacetyl-thymosin b 4 –79.4
o 0.12 14.8 4221.14
[Met(0)
6, Tyr(Me)
12]deacetyl-thymosin b 4 –83.7
o 0.13 15.3 4257.19
Met(0), methionine sulfoxide; Phe(4F), para-fluorophenylalanine.
a See Materials and methods for description of method.
b HPLC was performed on an analytical Nucleosil 5C18 column (4 ´ 150cm) by gradient elution with CH3CN (20
to > 45%) in 0.1% trifluoroacetic acid at a flow rate of 1ml/min, and eluate was monitored at 230nm.
c Found values were in agreement with calculated values.(obtained  from  protected  deacetyl-thymosin  b 4
3
without  reduction  treatment),  and  [Met(0)6,  Phe-
(4F)12]deacetyl-thymosin b 4 and [Met(0)6, Tyr(Me)12]-
deacetyl-thymosin  b 4,  was  administered  30min
before  (intraperitoneal  injection),  coincident  with
(intra-paw  injection)  and  6h  after  (intraperitoneal
injection)  carrageenin injection into  the  right  hind
footpad. The  change  in  footpad thickness between
right  and  left  hindlimbs  was  assessed  using  dial
calipers by two observers ‘blinded’ to the treatment
status of the mice. Control carrageenin-injected mice
received phosphate-buffered  saline at similar  times.
We judged our synthetic peptide had a positive effect
when we found more than 80% of footpad swelling
was suppressed (Tables 3 and 4).
Results and discussion
In  our  preceding  paper,3 we  reported  that  Phe12
residue of deacetyl-thymosin b 4 is one of the struc-
tural  essentials  for  immunological  activity  on  the
impaired blastogenic response of uremic T lympho-
cytes. One of our synthetic analogs,3,4 [Phe(4F)12]dea-
cetyl-thymosin b 4, exhibited stronger immunological
activity than that of our synthetic deacetyl-thymosin
b 4.
Recently, Young et al.2 reported that [Met(0)6]thy-
mosin  b 4 was  a  potent  inhibitor  of  carrageenin-
induced edema in the mouse paw.
These  results  prompted  us  to  synthesize  two
analogs, one of which has a fluorine atom on the para-
position of Phe12 and the other has methoxy group on
the para-position of Phe12 in [Met(0)6]deacetyl-thymo-
sin b 4.
Anti-inflammatory  effects  of  the  synthetic  [Met-
(0)6]deacetyl-thymosin b 4, [Met(0)6, Phe(4F)12]deace-
tyl-thymosin  b 4 and  [Met(0)6,  Tyr(Me)12]deacetyl-
thymosin b 4 were examined by carrageenin-induced
inflammation test using  BALB/c mice.2 The in vivo
anti-inflammatory effect of the synthetic peptides on
Carrageenin-induced edema in mouse paw
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Table 2. Amino acid ratios in 6N HCl hydrolysates of [Met(0)
6, Phe(4F)
12]deacetyl-thymosin b 4
and [Met(0)
6, Tyr(Me)
12]deacetyl-thymosin b 4
a
[Met(0)
6,
Phe(4F)
12]deacetyl-thymosin
b 4
[Met(0)
6,
Tyr(Me)
12]deacetyl-thymosin
b 4
Gly 1.00 (1) l.00 (1)
Leu 2.03 (2) 2.01 (2)
Ile 1.96 (2) 2.04 (2)
Met(0) 0.92 (1) 0.95 (1)
Ala 2.01 (1) 2.03 (1)
Pro 2.87 (3) 2.92 (3)
Ser 3.85 (4) 3.87 (4)
Thr 0.90 (3) 2.92 (3)
Glu 10.84 (11) 11.03 (11)
Asp 3.89 (4) 3.96 (4)
Lys 8.97 (9) 8.99 (9)
Phe(4F) 0.93 (1)
Tyr 0.96 (1)
Met(0), methionine sulfoxide; Phe(4F), para-fluorophenylalanine.
a Hydrolysis was carried out in 6N HCl in an evacuated sealed tube at 120°C for 30h, and the results are
expressed as ratios to the value for Gly, which was taken as the diagnostic amino acid in hydrolysates.
Table 3. Comparison of [Met(0)
6]deacetyl-thymosin b 4, [Met(0)
6, Phe(4F)
12]deacetyl-thymosin b 4
and [Met(0)
6, Tyr(Me)
12]deacetyl-thymosin b 4 by in vivo assay on suppression of carrageenin-
induced footpad swelling in the mouse paw
Peptide Dose (m g/kg) Suppression
effect of
mouse edema
a
–
b – –
[Met(0)
6]deacetyl-thymosin b 4 20 +
c
[Met(0)
6, Phe(4F)
12]deacetyl-thymosin b 4 10 +++
c
[Met(0)
6, Phe(4F)
12]deacetyl-thymosin b 4 20 ++++
c
[Met(0)
6, Tyr(Me)
12]deacetyl-thymosin b 4 20 ±
c
[Met(0)
6, Tyr(Me)
12]deacetyl-thymosin b 4 40 ±
c
Met(0), methionine sulfoxide; Phe(4F), para-fluorophenylalanine.
a From 10 to 40m g/kg of the peptides were injected into mouse paw.
b Control carrageenin-injected mice received phosphate-buffered saline at similar times.
c Order of suppression effect on mouse edema was as follows: ± < + < ++ < +++ < ++++.carrageenin-induced  edema  in  the  mouse  paw  is
presented in Table 3.
Interestingly,  our  synthetic  [Met(0)6,  Phe(4F)12]-
deacetyl-thymosin b 4 showed stronger anti-inflamma-
tory  activity  than  that  of  our  synthetic  [Met(0)6]-
deacetyl-thymosin  b 4.  In  this  study,  the  strong
electron-withdrawing  fluorine  atom  on  the  para-
position of the aromatic ring results in an analog that
possesses stronger activity than that of [Met(0)6]dea-
cetyl-thymosin b 4.
On  the  contrary,  another  analog,  [Met(0)6,  Tyr
(Me)12]deacetyl-thymosin  b 4, which has an electron-
donating group  –OCH3 on the  para-position of  the
aromatic ring, showed a much weaker anti-inflamma-
tory effect than that of our synthetic [Met(0)6]deace-
tyl-thymosin  b 4.  Our  synthetic  [Met(0)6]deacetyl-
thymosin  b 4 at  a  concentration  of  20 m g  induced
suppression equivalent to the suppression induced by
0.5mg/kg  dexamethasone,  a  potent  anti-inflamma-
tory steroid, and one of our two analogs, [Met(0)6,
Phe(4F)12]deacetyl-thymosin  b 4,  showed  the  same
suppression  activity  at  the  concentration  of  5 m g
induced  suppression  equivalent  to  the  suppression
induced by 0.5mg/kg dexamethazone, which means
that  suppression  activity  of  this  analog  is  about
fourfold  stronger  than  that  of  [Met(0)6]deacethyl-
thymosine b 4 (data not shown). These results seem to
suggest that aromaticity at the 12 position of [Met-
(0)6]deacetyl-thymosin  b 4 plays  significant  roles  for
anti-inflammatory  activity  on  carrageenin-induced
edema in the mouse paw, and modification of the Phe
residue of thymosin b 4 could produce more potent
analogs  capable  of  anti-inflammatory  effects  on
inflammatory diseases.
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Table  4.  Relative  potencies  of  synthetic  [Met(0)
6]deacetyl-thymosin  b 4 and  its  analogs  on
suppression of carrageenin-induced footpad swelling in the mouse paw
Peptide Relative potency (molar basis)
[Met(0)
6]deacetyl-thymosin b 4 1.00
[Met(0)
6, Phe(4F)
12]deacetyl-thymosin b 4 2.52
[Met(0)
6, Tyr(Me)
12]deacetyl-thymosin b 4 0.11
Met(0), methionine sulfoxide; Phe(4F), para-fluorophenylalanine.